Answers are grounded in this paper and cite their sources.
For the first time, a population approach was used to describe abacavir (ABC) pharmacokinetics in HIV-infected pregnant and nonpregnant women. A total of 266 samples from 150 women were obtained. No covariate effect (from age, body weight, pregnancy, or gestational age) on ABC pharmacokinetics was found. Thus, it seems unnecessary to adapt the ABC dosing regimen during pregnancy.
No takes yet. Share an insight, caveat, or question.
Fauchet et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: